A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as [intervention], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.

Drug: Allopurinol, Drug: Cytarabine, Drug: Daunorubicin Hydrochloride, Drug: Vincristine Sulfate, Drug: Dexamethasone, Drug: Pegylated L-Asparaginase, Drug: Methotrexate, Procedure: Bone Marrow Aspiration and Biopsy, Drug: Cyclophosphamide, Drug: Mercaptopurine, Biological: Rituximab, Drug: Doxorubicin, Drug: Thioguanine, Biological: Inotuzumab Ozogamicin, Other: Laboratory Biomarker Analysis